Dr. Ledermann Discusses Olaparib in Ovarian Cancer

Video

Jonathan Ledermann, BSc, MD, FRCP, Professor of Medical Oncology in the UCL Cancer Institute, University College London, discusses health-related quality of life during olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation.

Jonathan Ledermann, BSc, MD, FRCP, Professor of Medical Oncology in the UCL Cancer Institute, University College London, discusses health-related quality of life during olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation.

Ledermann explains that olaparib is a PARP inhibitor, which is an active group of drugs in patients with ovarian cancer. This agent is particularly active if the patient has platinum-sensitive disease and especially in those that carry a BRCA mutation.

The Study19 Trial was conducted to examine the activity of olaparib in patients who had platinum-sensitive relapsed serous ovarian cancer, Ledermann says. The patients in the trial had a BRCA mutation or had high-grade serous cancer but no mutation. The study showed that there was a highly significant improvement in the progression-free survival in both the patients with the BRCA mutation and the wild-type patients but the greatest benefit was seen in those with the mutation, Ledermann says. ​

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD